Langer lab spinout Lyndra raises $65M in bid to replace existing HIV, schizophrenia, opioid abuse treatments

Two months after unveiling Phase II data for their long-acting schizophrenia pill, Lyndra Therapeutics has raised a $65 million Series C to push it through a pivotal trial.

The new round, led by the VC arm of insurance giant AIG, brings Lyndra’s total funding to over $160 million as they...

Click to view original post